Deciphera Pharmaceuticals, Inc.
- Jurisdiction
United States - LEI
529900QR4WAPYY0CBF25 - ISIN
US24344T1016 (DCPH )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
3
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
2
/ 7
Profile
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Read full profile
Fundamentals
- Net revenue
€149.19M - Gross margin
96.0% - EBIT
-€176.18M - EBIT margin
-118.1% - Net income
-€162.42M - Net margin
-108.9%
Statement period: - (published )
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
No insider transactions in the last 90 days. View older insider transactions
Earnings Calls
Earnings Calls
Latest earnings call: February 6, 2024 (Q4 2023)